Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy

PURPOSE OF REVIEW: Patients who have parkinsonian features, especially without tremor, that are not responsive to levodopa, usually have one of these three major neurodegenerative disorders rather than Parkinson disease: progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD). Each of these disorders eventually develops signs and symptoms that distinguish it from idiopathic Parkinson disease, but these may not be present at disease onset. Although these conditions are not generally treatable, it is still important to correctly diagnose the condition as soon as possible.

RECENT FINDINGS: In recent years, it has been increasingly recognized that the symptoms of these diseases do not accurately predict the pathology, and the pathology does not accurately predict the clinical syndrome. Despite this, interest has grown in treating these diseases by targeting misfolded tau (in the case of PSP and CBD) and misfolded α-synuclein (in the case of MSA).

SUMMARY: Knowledge of the characteristic signs and symptoms of PSP, MSA, and CBD are essential in diagnosing and managing patients who have atypical parkinsonian syndromes.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:25

Enthalten in:

Continuum (Minneapolis, Minn.) - 25(2019), 4 vom: 01. Aug., Seite 919-935

Sprache:

Englisch

Beteiligte Personen:

Greene, Paul [VerfasserIn]

Links:

Volltext

Themen:

46627O600J
Case Reports
Dopamine Agents
Journal Article
Levodopa
Review

Anmerkungen:

Date Completed 21.01.2020

Date Revised 21.01.2020

published: Print

Citation Status MEDLINE

doi:

10.1212/CON.0000000000000751

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM299679306